Pharvaris (PHVS) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 219.86% |
| Mar 31, 2026 | 15.88% |
| Dec 31, 2025 | -25.31% |
| Sep 30, 2025 | -183.87% |
| Jun 30, 2025 | 205.93% |
| Mar 31, 2025 | -32.34% |
| Dec 31, 2024 | 19.56% |
| Sep 30, 2024 | -243.52% |
| Jun 30, 2024 | 205.25% |
| Mar 31, 2024 | 13.79% |
| Dec 31, 2023 | -37.25% |
| Sep 30, 2023 | -100.00% |
| Jun 30, 2023 | 98,026,160.71% |
| Mar 31, 2023 | 39.35% |
| Dec 31, 2022 | -380.41% |
| Sep 30, 2022 | -100.00% |
| Jun 30, 2022 | 75,439,311.17% |
| Mar 31, 2022 | -27.62% |
| Dec 31, 2021 | -30.65% |
| Sep 30, 2021 | -158.89% |